MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands.
暂无分享,去创建一个
P. Sonneveld | M. Jongen‐Lavrencic | O. Visser | P. Huijgens | A. Dinmohamed | A. A. van de Loosdrecht | E. Posthuma
[1] V. Arndt,et al. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. , 2017, Cancer epidemiology.
[2] E. Roman,et al. Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15 , 2016, Cancer epidemiology.
[3] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[4] P. Sonneveld,et al. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry , 2015, Leukemia.
[5] P. Sonneveld,et al. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. , 2015, Leukemia research.
[6] M. Ballesteros,et al. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts , 2015, Annals of Hematology.
[7] P. Sonneveld,et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. , 2014, European journal of cancer.
[8] M. Cazzola,et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.
[9] U. Germing,et al. Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. , 2013, Leukemia research.
[10] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[11] Z. Estrov,et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. , 2011, Blood.
[12] F. Berrino,et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.
[13] N. Howlader,et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. , 2008, Blood.
[14] S. Mayne,et al. Myelodysplastic syndromes , 2007, Cancer.
[15] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.